MSB 6.45% $1.16 mesoblast limited

seems like a way off but focussing on the positiveslast trial 3...

  1. 572 Posts.
    lightbulb Created with Sketch. 294
    seems like a way off but focussing on the positives

    last trial
    3 years to enroll, then 24 months to endpoint, 400 patients, 3 groups, complicated endpoint

    this trial
    1 year to enroll, then 12 month endpoint, 300 patients, 2 groups. >5 years injury excluded, (replicate prior results achieved) simple pain endpoint.

    knowns - who to treat, when to treat, what mixture to treat them with, which clinics to do it, how it helps.

    this trial is much less exploratory. but its still pivotal, so cant exactly call it a "confirmatory efficacy" trial. i have limited understanding of statistics but i would think (even with reduced enrollment numbers) that by removing 1 treatment arm , and exluding a certain non responding group from enrollment they would more likely achieve a stronger statistical significance between groups than last round.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.16
Change
0.070(6.45%)
Mkt cap ! $1.318B
Open High Low Value Volume
$1.12 $1.20 $1.11 $20.88M 17.94M

Buyers (Bids)

No. Vol. Price($)
5 59978 $1.15
 

Sellers (Offers)

Price($) Vol. No.
$1.16 34019 3
View Market Depth
Last trade - 16.10pm 06/05/2024 (20 minute delay) ?
Last
$1.15
  Change
0.070 ( 5.63 %)
Open High Low Volume
$1.12 $1.20 $1.12 3733217
Last updated 15.59pm 06/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.